Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 1/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7157728 | 0.84 | METAP2 (0.37) | METAP2METAP1 | |
| SCHEMBL11498402 | 0.81 | METAP2 (0.39) | METAP2METAP1NPY5R | |
| SCHEMBL3578263 | 0.75 | METAP2 (0.44) | METAP2METAP1FPR1NPY5R | |
| SCHEMBL434033 | 0.75 | METAP2 (0.44) | METAP2METAP1NPY5R | |
| SCHEMBL30895599 | 0.72 | METAP2 (0.42) | METAP2METAP1FPR1NPY5R | |
| SCHEMBL8741745 | 0.71 | METAP2 (0.38) | METAP2METAP1FPR1 | |
| SCHEMBL4412912 | 0.71 | ADORA2A (0.49) | — | |
| SCHEMBL6472456 | 0.71 | METAP2 (0.45) | METAP2METAP1NPY5R | |
| SCHEMBL277596 | 0.69 | METAP2 (0.51) | METAP2METAP1NPY5R | |
| SCHEMBL2968462 | 0.69 | METAP2 (0.47) | METAP2METAP1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | claimed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | claimed |
| US-20180162898-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2018-06-14 | — | — | US | claimed |
| EP-3131914-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | Idenix Pharmaceuticals LLC (US) | 2017-02-22 | — | — | EP | claimed |
| EP-1292603-B1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-22 | — | — | EP | claimed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | claimed |
| EP-3083654-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | Idenix Pharmaceuticals LLC (US) | 2016-10-26 | — | — | EP | claimed |
| US-20160280729-A1 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-09-29 | — | — | US | claimed |
| CN-104163841-B | For treating 2 ' and 3 '-nucleoside prodrugs of the modification of flaviviridae infections | 埃迪尼克斯医药公司 | 2016-08-24 | — | — | CN | claimed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| US-20040254141-A1 | 2'-Fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-16 | — | — | US | claimed |
| US-20040181051-A1 | Process for the production of 3'-nucleoside prodrugs | STORER RICHARD (GB) | 2004-09-16 | — | — | US | claimed |
| WO-2004058792-A1 | PROCESS FOR THE PRODUCTION OF 3'-NUCLEOSIDE PRODRUGS | IDENIX (CAYMAN) LIMITED (KY) | 2004-07-15 | — | — | WO | claimed |
| WO-2004046331-A2 | 2’-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-03 | — | — | WO | claimed |
| US-20040087806-A1 | Processes for preparing 1,3-dioxolane nucleosides | PHARMASSET, INC. | 2004-05-06 | — | — | US | claimed |
| WO-2004028445-A2 | PROCESSES FOR PREPARING 1,3-DIOXOLANE NUCLEOSIDES | PHARMASSET INC. (US) | 2004-04-08 | — | — | WO | claimed |
| US-6518425-B1 | A process for producing a 1,3-oxathiolane nucleoside comprising reacting a 5-halo-2-protected-oxymethyl-1,3-oxathiolane with a silylated purine or pyrimidine without the addition of a Lewis acid or an additional base to the reaction | EMORY UNIVERSITY | 2003-02-11 | — | — | US | claimed |
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | APOTEX PHARMACHEM INC (CA) | 2003-01-16 | — | — | US | claimed |
| WO-1992017485-A1 | PREPARATION OF 3'-SUBSTITUTED-2',3'-DIDEOXYNUCLEOSIDES AND 2'-DEOXYNUCLEOSIDES FROM ACYCLIC, ACHIRAL PRECURSORS | EMORY UNIVERSITY (US) | 1992-10-15 | — | — | WO | claimed |
| WO-1992010496-A1 | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-06-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254141-A1 | 2'-Fluoronucleosides | NSUN2, PNP, FDPS | METAP2 193/4885METAP1 247/4885FPR1 270/4885 |
| US-20160280729-A1 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | ZC3HAV1, HAVCR2, NSUN2 | METAP2 825/4885METAP1 343/4885FPR1 202/4885 |
| US-20040087806-A1 | Processes for preparing 1,3-dioxolane nucleosides | NUDT1, PNP, DPYD | METAP2 3005/4885METAP1 1753/4885FPR1 1414/4885 |
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | SLC29A1, NUDT1, SLC28A1 | METAP2 1203/4885METAP1 572/4885FPR1 2799/4885 |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | METAP2 1361/4885METAP1 2339/4885FPR1 3156/4885 |
| US-20040181051-A1 | Process for the production of 3'-nucleoside prodrugs | PNP, GART, UMPS | METAP2 1016/4885METAP1 861/4885FPR1 1893/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | METAP2 1396/4885METAP1 2385/4885FPR1 3174/4885 |
| US-20180162898-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | NSUN2, NSUN3, ZC3HAV1 | METAP2 733/4885METAP1 443/4885FPR1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.